Eli Lilly (LLY +2.69%) has achieved impressive returns in recent years, driven by soaring demand for tirzepatide, a medicine sold as Mounjaro for diabetes and Zepbound (in certain markets) for obesity ...
LLY delivered 48% revenue growth and raised full-year EPS guidance, yet shares sit nearly 30% below the $1,500 price target within reach. Retatrutide's BLA filing, Foundayo scaling past 36,000 ...
Dr. Terry Anderson of Lilly Grove Baptist Church in Houston closed the Baptist Ministers’ Conference Citywide Revival with a timely message from Isaiah 6, challenging pastors and believers to ...
Lilly is best known for its popular obesity and diabetes medicines, overshadowing its efforts to develop medicines for many other conditions. The massive sales windfall from Zepbound and Mounjaro has ...
Eli Lilly said on Monday it would acquire privately held Merida Biosciences for up to $2.88 billion in cash, strengthening its immunology portfolio with an experimental treatment for thyroid-related ...
Deal helps Lilly expand immunology pipeline, diversify beyond obesity drugs Merida's lead drug candidate targets Graves' disease and thyroid eye disease Transaction valued at up to $2.88 billion in ...
The Food and Drug Administration approved Eli Lilly's diabetes drug Mounjaro to cut down the risk of heart attack or stroke in high-risk adults with Type 2 diabetes. The approval gives consumers ...
As its world-leading GLP-1 earns more than any other medicine — and its market cap eclipses all other healthcare companies — Eli Lilly has decided to stop disclosing its Phase 1 pipeline ...
NACOGDOCHES, Texas (PRESS RELEASE) - This notice has been issued due to a large leak on FM 343/CR 821, the Texas Commission on Environmental Quality has required the Lilly Grove SUD #1740014, public ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results